Literature DB >> 15913873

The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.

Johan P Rung1, Arvid Carlsson, Katarina Rydén Markinhuhta, Maria L Carlsson.   

Abstract

Schizophrenia is manifested by positive and negative symptoms, as well as cognitive deficits. Most existing antipsychotic agents have poor effects on the negative symptoms of schizophrenia, thus emphasizing the necessity for developing new antipsychotic treatments. Dopaminergic stabilizers constitute one of the latest novelties in the quest for new antipsychotic drugs. Social withdrawal in rats, in response to treatment with NMDA-receptor antagonists such as (+)-MK-801, may be used to model negative symptoms. In this study we aimed to evaluate the dopaminergic stabilizers (-)-OSU6162 and ACR16, compared to haloperidol and clozapine, in a rat model for schizophrenia, focusing on (+)-MK-801 induced social withdrawal. Social behaviour and motor activity were assessed using a videotracking system, allowing automated analysis of the behaviour. Both (-)-OSU6162 and ACR16 were capable of restoring social behaviour, measured as proximity, to control level. These results indicate that these drugs may be effective in the treatments of negative symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913873     DOI: 10.1016/j.pnpbp.2005.03.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  17 in total

1.  Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Authors:  Johan P Rung; Emilia Rung; Lisa Helgeson; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

2.  Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.

Authors:  Johan P Rung; Emilia Rung; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

3.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07

Review 4.  Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy.

Authors:  Katherine E Burdick; Raphael J Braga; Joseph F Goldberg; Anil K Malhotra
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.

Authors:  V Labrie; W Wang; S W Barger; G B Baker; J C Roder
Journal:  Genes Brain Behav       Date:  2009-08-05       Impact factor: 3.449

6.  Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity.

Authors:  Vívian T da Silveira; Jivago Röpke; Ana L Matosinhos; Ana C Issy; Elaine A Del Bel; Antônio C de Oliveira; Fabrício A Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-24       Impact factor: 3.000

Review 7.  Brain in flames - animal models of psychosis: utility and limitations.

Authors:  Daniele Mattei; Regina Schweibold; Susanne A Wolf
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-27       Impact factor: 2.570

8.  Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Authors:  Ferdinando Squitieri; Justo Garcia de Yebenes
Journal:  Drug Des Devel Ther       Date:  2015-10-28       Impact factor: 4.162

9.  Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Authors:  João V Nunes; Patricia A Broderick
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

10.  Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.

Authors:  Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2015-07-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.